Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906377 | 0.84 | TLR9 (0.40) | TLR9TLR8TLR7MAP4K4GCK | |
| SCHEMBL14314255 | 0.81 | TLR9 (0.38) | TLR9TLR8TLR7MEN1KMT2A | |
| SCHEMBL9906379 | 0.81 | MLYCD (0.36) | TLR9TLR8TLR7 | |
| SCHEMBL17480649 | 0.80 | CDK2 (0.39) | TLR9TLR8TLR7 | |
| SCHEMBL9906382 | 0.80 | TLR9 (0.36) | TLR9TLR8TLR7HTR4 | |
| SCHEMBL23137881 | 0.77 | CCNE1 (0.37) | MAP4K3KMT2A | |
| SCHEMBL23136937 | 0.77 | CCNE1 (0.37) | TLR9TLR8TLR7MAP4K3 | |
| SCHEMBL9906380 | 0.76 | MAP3K12 (0.36) | TLR9TLR8TLR7HTR4KDM2B | |
| SCHEMBL23137885 | 0.76 | CCNE1 (0.36) | MAP4K3KMT2A | |
| SCHEMBL21872198 | 0.76 | CCNE1 (0.36) | MAP4K3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198308-B2 | Chemical compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20110059938-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20080182837-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059938-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | TLR9 4403/4885TLR8 4767/4885TLR7 3658/4885 |
| US-20080182837-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | TLR9 4403/4885TLR8 4767/4885TLR7 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.